|View printer-friendly version|
|Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update|
"With the completion of our recent IPO, Audentes is well capitalized to advance a robust pipeline of gene therapy products for the treatment of serious, life-threatening rare diseases," stated
Third Quarter 2016 Financial Results
For more information regarding Audentes, please visit www.audentestx.com.
Forward Looking Statements
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-reports-third-quarter-2016-financial-results-and-provides-corporate-update-300360393.html